Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 10, 2015, Pages 4451-4456

  Xie, Z R ^a   Luo, Y L ^a   Xiao, F M ^a   Liu, Q ^a   Ma, Y ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver resection; Quality of life; Transcatheter arterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LIVER NEOPLASMS; LIVER RESECTION; MALE; MENTAL HEALTH; MIDDLE AGED; PATHOLOGY; PSYCHOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDY; TIME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MENTAL HEALTH; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84930742531     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.10.4451     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, et al (2011). CA Cancer J Clin, 61, 69-90.
2. Maluccio M, Covey A (2012). Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 62, 394-9.
3. Bruix J, Gores GJ, Mazzaferro V (2014). Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 63, 844-55.
4. Zuo CH, Xia M, Liu JS, et al (2015). Transcatheter arterial chemoembolization combined with interferon-alpha is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev, 16, 245-51.
5. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2.
6. Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6.
7. Marrero JA, Fontana RJ, Barrat A, et al (2005). Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatol, 41, 707-16.
8. Zhong JH, Ke Y, Gong WF, et al (2014). Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg, 260, 329-40.
9. Jianyong L, Lunan Y, Wentao W, et al (2014). Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore), 93, 180.
10. Slevin ML (1992). Quality of life: philosophical question or clinical reality? BMJ, 305, 466-9.
11. Han KT, Park EC, Kim SJ, et al (2014). Factors affecting the quality of life of Korean cancer survivors who return to the workplace. Asian Pac J Cancer Prev, 15, 8783-8.
12. Langenhoff BS, Krabbe PF, Wobbes T, et al (2001). Quality of life as an outcome measure in surgical oncology. Br J Surg, 88, 643-52.
13. Scurtu R, Groza N, Otel O, et al (2005). Quality of life in patients with esophagojejunal anastomosis after total gastrectomy for cancer. Rom J Gastroenterol, 14, 367-72.
14. Diouf M, Bonnetain F, Barbare JC, et al (2015). Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist, 20, 62-71.
15. Diouf M, Filleron T, Barbare JC, et al (2013). The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol, 58, 509-21.
16. Yeo W, Mo FK, Koh J, et al (2006). Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol, 17, 1083-9.
17. Gandhi S, Khubchandani S, Iyer R (2014). Quality of life and hepatocellular carcinoma. J Gastrointest Oncol, 5, 296-317.
18. Fan SY, Eiser C, Ho MC (2010). Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol, 8, 559-64.
19. Bruns H, Kratschmer K, Hinz U, et al (2010). Quality of life after curative liver resection: a single center analysis. World J Gastroenterol, 16, 2388-95.
20. Mise Y, Satou S, Ishizawa T, et al (2014). Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg, 38, 958-67.
21. Xing M, Webber G, Prajapati HJ, et al (2015). Preservation of quality of life with doxorubicin drug eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: longitudinal prospective study. J Gastroenterol Hepatol, [Epub ahead of print].
22. Wang YB, Chen MH, Yan K, et al (2007). Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res, 16, 389-97.
23. Toro A, Pulvirenti E, Palermo F, et al (2012). Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment. Surg Oncol, 21, 23-30.
24. Li L, Wang H, Shen Y (2002). Development and psychometric tests of a Chinese version of the SF-36 Health Survey Scales. Zhonghua yu fang yi xue za zhi, 36, 109-13.
25. Jin S, Yan L, Li B, et al (2010). Quality of life and psychologic distress of recipients after adult living-donor liver transplantation (LDLT)-A study from mainland China. Transplant Proc, 42, 2611-6.
26. Zhang T, Zeng Y, Huang J, et al (2014). Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: a single-center experience. J Surg Res, 191, 370-8.
27. Jiang L, Lei JY, Wang WT, et al (2014). Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE. J Gastrointest Surg, 18, 1125-30.
28. Mancuso A, Mazzola A, Cabibbo G, et al (2015). Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. Dig Liver Dis, 47, 324-30
29. Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. Asian Pac J Cancer Prev, 14, 7367-9.
30. Schipper H, Clinch J, McMurray A, et al (1984). Measuring the quality of life of cancer patients: the functional living indexcancer: development and validation. J Clin Oncol, 2, 472-83.
31. Steel JL, Geller DA, Robinson TL, et al (2014). Health-related quality of life as a prognostic factor in patients with advanced cancer. Cancer, 120, 3717-21.
32. Martin RC, Eid S, Scoggins CR, et al (2007). Health-related quality of life: return to baseline after major and minor liver resection. Surgery, 142, 676-84.
33. Poon RT, Fan ST, Yu WC, et al (2001). A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg, 136, 693-9.